IDEMIA
IDEMIA will supply KT Corporation its eXtra One 5G USIM (Universal Subscriber Identity Module), a dedicated 5G SIM card giving enhanced subscriber privacy protection and fast, seamless connectivity in South Korea, while marking a big development leap forward and boosting consumer 5G handset adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005442/en/
IDEMIA, the global leader in Augmented Identity, today announced it plans to team up with KT Corporation (formerly Korea Telecomm) to launch KTC’s first standalone (SA) 5G USIM card in Asia-Pacific in support of their new 5G standalone network.
Under this partnership, IDEMIA will supply KTC 5G standalone USIM cards with NFC (near-field communication) features. The 5G standalone USIM delivers better security for MNO (Mobile Network Operator) network customers as the cards are specially designed to protect customer privacy. Through the USIMs IMSI (International Mobile Subscriber Identity) encryption capability, MNO customer private data such as location and network usage habits will be protected by the fact that mobile users’ IMSI numbers are encrypted before transmission to networks. The card safeguards MNOs’ control over their 5G security and data. Compliant with global privacy regulations and recommended by the Trusted Connectivity Alliance (TCA), 5G USIM cards are also compatible with 5G non-stand alone (NSA) networks, 4G networks and South Korea’s NFC contactless payment schemes.
“We constantly push the boundaries at IDEMIA, and launching our eXtra One 5G SA USIM cards in Asia for the first time is testament to this. We have worked with KT Corporation for many years going back to the 3G era, and we are thrilled to join forces once more to bring to market a truly groundbreaking product. We look forward to support their efforts in delivering a smoother, more modern experience to South Korean customers,” said Benson Yeo, IDEMIA Asia Pacific Mobile Operators Vice President.
“It’s just a matter of time before 5G becomes the new global communication standard. We partner with IDEMIA to stay ahead of the curve and ensure that our users’ privacy and data are totally safe while they enjoy the benefits of our 5G networks. Our past great teamwork with IDEMIA gives us confidence they have the expertise and capability to create these game-changing 5G SA USIM cards for our customers”, said Joon-Ho Lee, Device Team Leader, Device Division, KT Corporation.
-END-
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About IDEMIA’s Mobile Operators Business unit
IDEMIA serves clients in 180 countries and is trusted by over 500 mobile operators globally. With over 900 million SIM cards, 100 + eSIM platform references and over 2.2 eSIM consumer transactions in 2020, IDEMIA is leading the way in eSIM and remote subscription management for consumer and M2M spaces and end-to-end biometric solutions. Making MNOs the next identity providers. IDEMIA benefits from its global manufacturing footprint (Brazil, France, India and China) and cutting-edge security data centers in Europe and the United States. Our solutions are trusted by the largest Groups worldwide. Our continuous innovation is fueled by strong R&D investments and close partnerships in IoT/M2M - Connectivity - Biometrics – Security – Encryption – QoS/QoE – Advanced SIM & services areas.
About KT Corporation
KT Corp., Korea's largest telecommunications service provider, is leading the new era of innovations in one the world's most connected countries with 5G, Big Data, Cloud, IoT, Blockchain and other transformative technologies. KT launched the world's first nationwide commercial 5G network in April 2019, after showcasing the first trial 5G services at the PyeongChang Winter Olympic Games in February 2018. To help cope with COVID-19, KT is staging a social campaign, dubbed "Ma-Eum:TACT (Heart to Heart)," providing technology support for people and businesses in need. KT will deliver most essential and innovative services and solutions to its customers around the world as the first frontier in the next technology revolution and number one Global ICT Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom